Information Provided By:
Fly News Breaks for April 27, 2017
ESRX, CVS, ANTM
Apr 27, 2017 | 09:03 EDT
Leerink analyst Ana Gupte raised her price target for Anthem (ANTM) to $210 from $200 as she believes the company holds all the cards in the ongoing PBM re-contracting with multiple players across Optum, Prime and CVS Health (CVS), while Express Scripts (ESRX) is still an option based on Anthem's commentary. Further, Repeal and Replace offers certainty on the HIPF tax repeal with upside in 2018 and paves the way for corporate tax reform with 15%-30% upside, he argues. The analyst reiterates an Outperform rating on Anthem's shares.
News For ANTM;CVS;ESRX From the Last 2 Days
There are no results for your query ANTM;CVS;ESRX